Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ertugliflozin→

Ertugliflozin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1210344-57-2
Molecular formula
C22H25ClO7
Molecular weight
436.9 g/mol
Drug class
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitororal antihyperglycaemic
Mechanism of action
Inhibits SGLT2 in the proximal renal tubule, reducing renal glucose reabsorption and increasing urinary glucose excretion, which lowers blood glucose.
Indications / reported uses
  • Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus; product-specific labels may include use in combination with sitagliptin or metformin

Sources: US DailyMed — STEGLATRO (ertugliflozin) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ertugliflozin Environmental Risk Assessment (ERA) (the Ertugliflozin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.